Literature DB >> 2295233

Established ARDS treated with a sustained course of adrenocortical steroids.

R G Hooper1, R A Kearl.   

Abstract

Short treatment courses of ACS have been shown to be of no demonstrable value in the treatment of ARDS. We gave two patients with persistant ARDS a trial of ACS after they demonstrated pulmonary uptake of 67Ga. Brief initial improvement disappeared with tapering of the ACS. A sustained course of ACS led to resolution of the ARDS in both patients. In all, ten patients with established ARDS were treated with sustained ACS over an 18-month period. The eight additional patients had uninterrupted courses of therapeutic ACS for greater than 21 days. The patients averaged 12 days of greater than 40 mg a day. At the time of treatment, all patients had established ARDS, meeting for at least 72 hours, criteria for the diagnosis of ARDS. A sustained course of ACS may be effective in the treatment of selected patients with established ARDS. Controlled studies of established ARDS are indicated to define the characteristics of these patients and their management.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295233     DOI: 10.1378/chest.97.1.138

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  17 in total

Review 1.  The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.

Authors:  J Cranshaw; M J D Griffiths; T W Evans
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

2.  Acute respiratory distress syndrome: a historical perspective.

Authors:  Gordon R Bernard
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

3.  Recovery from adult respiratory distress syndrome after high dose corticosteroids.

Authors:  S L Ho; G A Lewis; D W Young
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

4.  Clinical Aspects of Acute Lung Insufficiency (ALI/TRALI).

Authors:  Matthias Hecker; Hans-Dieter Walmrath; Werner Seeger; Konstantin Mayer
Journal:  Transfus Med Hemother       Date:  2008-03-10       Impact factor: 3.747

5.  The potential role of BAX and BCL-2 expression in diffuse alveolar damage.

Authors:  D Guinee; E Brambilla; M Fleming; T Hayashi; M Rahn; M Koss; V Ferrans; W Travis
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

Review 6.  Intensive care.

Authors:  S Sinclair; M Singer
Journal:  Postgrad Med J       Date:  1993-05       Impact factor: 2.401

7.  Corticosteroids and "chronic" ARDS.

Authors:  S C Donnelly
Journal:  Ir J Med Sci       Date:  1995-01       Impact factor: 1.568

Review 8.  Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.

Authors:  Magda Cepkova; Michael A Matthay
Journal:  J Intensive Care Med       Date:  2006 May-Jun       Impact factor: 3.510

9.  Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature.

Authors:  G Umberto Meduri; Paul E Marik; George P Chrousos; Stephen M Pastores; Wiebke Arlt; Albertus Beishuizen; Faran Bokhari; Gary Zaloga; Djillali Annane
Journal:  Intensive Care Med       Date:  2007-11-14       Impact factor: 17.440

10.  The role of gallium-67 scintigraphy in diagnosing sources of fever in ventilated patients.

Authors:  G U Meduri; J M Belenchia; J D Massie; M Eltorky; E A Tolley
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.